Zim Laboratories Profile
Key Indicators
- Authorised Capital ₹ 75.00 Cr
- Paid Up Capital ₹ 48.73 Cr
- Company Age 40 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 150.19 Cr
- Satisfied Charges ₹ 501.82 Cr
- Revenue Growth 20.65%
- Profit Growth 92.19%
- Ebitda 34.95%
- Net Worth 14.15%
- Total Assets -0.17%
About Zim Laboratories
Zim Laboratories Limited. (ZLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 14 February 1984 and has a history of 40 years and 11 months. Its registered office is in Nagpur, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 541400.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 75.00 Cr and a paid-up capital of Rs 48.73 Cr.
The company currently has active open charges totaling ₹150.19 Cr. The company has closed loans amounting to ₹501.82 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Zim Laboratories Limited. India are Shyam Patro as CFO and Piyush Nikhade as Company Secretary. Anwar Daud, Zulfiquar Kamal, Prakash Sapkal, and Five other members serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L99999MH1984PLC032172
- Company No.
032172
- Stock Symbol
BSE : 541400
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Feb 1984
- Date of AGM
10 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
What products or services does Zim Laboratories Limited. offer?
Zim Laboratories Limited. offers a wide range of products and services, including ISO & Quality Management Consultants, Certification Services, Digestive System Drugs & Medicines, Anti Ulcer Drugs, Pharma Ingredients & Raw Materials, Anti Infective API, Herbal Capsules, Cardiac Drugs, Blood Pressure Medicine, Indapamide Tablet.
Who are the key members and board of directors at Zim Laboratories?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anwar Daud  | Managing Director | 01-Apr-2009 | Current |
| Shyam Patro | CFO | 01-Apr-2019 | Current |
| Piyush Nikhade | Company Secretary | 01-Sep-2017 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Zulfiquar Kamal | Whole-Time Director | 19-Oct-2012 | Current |
| Prakash Sapkal | Whole-Time Director | 22-Nov-2013 | Current |
| Niraj Dhadiwal | Whole-Time Director | 22-Nov-2013 | Current |
| Kavita Loya | Director | 21-Sep-2017 | Current |
| Padmakar Joshi | Director | 21-Sep-2017 | Current |
| Kakasaheb Mahadik | Director | 01-Apr-2022 | Current |
Financial Performance of Zim Laboratories.
Zim Laboratories Limited., for the financial year ended 2023, experienced significant growth in revenue, with a 20.65% increase. The company also saw a substantial improvement in profitability, with a 92.19% increase in profit. The company's net worth Soared by an impressive increase of 14.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zim Laboratories?
In 2023, Zim Laboratories had a promoter holding of 33.26% and a public holding of 66.74%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zim Health Technologies LimitedAnwar Daud and Zulfiquar Kamal are mutual person
- Zim Thinorals Private Limited
Anwar Daud, Zulfiquar Kamal and 1 more are mutual person
- Falcon Knowledge Services Private Limited
Zulfiquar Kamal is a mutual person
- Octave Business Management Services Private Limited
Zulfiquar Kamal is a mutual person
Charges (Loans)
₹150.19 Cr
₹501.82 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 140.19 Cr
- Tata Capital Financial Services Limited : 10.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Oct 2023 | Tata Capital Financial Services Limited | ₹10.00 Cr | Open |
| 01 Feb 2013 | Bank Of India | ₹140.19 Cr | Open |
| 26 May 2023 | Others | ₹15.00 Cr | Satisfied |
| 13 Jan 2022 | Others | ₹5.50 Cr | Satisfied |
| 29 Dec 2021 | Tata Capital Financial Services Limited | ₹15.00 Cr | Satisfied |
How Many Employees Work at Zim Laboratories?
Zim Laboratories has a workforce of 583 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zim Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zim Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
